Drug Profile
Research programme: breast cancer therapy - ChemRegen
Latest Information Update: 28 Sep 2020
Price :
$50
*
At a glance
- Originator ChemRegen
- Class Antineoplastics; Small molecules
- Mechanism of Action Signal transduction pathway inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Breast cancer
Most Recent Events
- 28 Sep 2020 No recent reports of development identified for preclinical development in Breast-cancer in USA
- 01 Aug 2016 Preclinical trials in Breast cancer in USA (unspecified route)